---
layout: post
title: "Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments"
date: 2026-02-05 18:58:13 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-03926
original_published: 2022-02-24 00:00:00 +0000
significance: 8.00
---

# Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** February 24, 2022 00:00 UTC
**Document Number:** 2022-03926

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public meeting entitled "Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA)" (the Program) and an opportunity for public comment. The topics to be discussed are the final assessment and public stakeholder views of the Program.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/02/24/2022-03926/final-assessment-of-the-program-for-enhanced-review-transparency-and-communication-in-the-biosimilar)
- API: https://www.federalregister.gov/api/v1/documents/2022-03926

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
